Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel

Manabu Seino; Tsuyoshi Ohta; Akiko Sugiyama; Hirotsugu Sakaki; Takeshi Sudo; Seiji Tsutsumi; Shogo Shigeta; Hideki Tokunaga; Masafumi Toyoshima; Nobuo Yaegashi; Satoru Nagase

doi:10.18632/oncotarget.25868

Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel

Manabu Seino, Tsuyoshi Ohta, Akiko Sugiyama, Hirotsugu Sakaki, Takeshi Sudo, Seiji Tsutsumi, Shogo Shigeta, Hideki Tokunaga, Masafumi Toyoshima, Nobuo Yaegashi, Satoru Nagase

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Introduction: Uterine serous carcinoma (USC) is more aggressive than other subtypes of endometrial carcinoma and is associated with a poor prognosis. We analyzed the metabolomic profile of USC with acquired resistance to paclitaxel. Results: Glutathione (GSH) concentration in PTX-1 cells was higher than in USPC- 1 cells. In addition, GSH concentration in the USPC-1 cells increased after treatment with paclitaxel but was unchanged in PTX-1 cells. Glucose-6-phosphate (G6P) and ribose-5-phosphate (R5P) concentrations in PTX-1 cells were higher than those in USPC-1 cells. G6P concentration in the USPC-1 cells was unchanged after treatment with paclitaxel, while it decreased in PTX-1 cells. Conclusion: Our results indicate that increased GSH and glucose metabolism may be related to acquiring resistance to paclitaxel in USC and thus may be targets for anti-USC therapy. Materials and Methods: We compared metabolic profiles and reactions to paclitaxel in both a wild type USC cell line (USPC-1) and PTX-1, a cell line derived from USPC-1 which acquired paclitaxel resistance, using a capillary electrophoresis CE-MS/MS system.

Original language	English
Pages (from-to)	31985-31998
Number of pages	14
Journal	Oncotarget
Volume	9
Issue number	62
DOIs	https://doi.org/10.18632/oncotarget.25868
Publication status	Published - 2018 Aug 10

Keywords

Endometrial cancer
Metabolomic analysis
Paclitaxel
Uterine serous carcinoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.18632/oncotarget.25868

Cite this

@article{7f218acff06a4240b9936ecbe388d69f,

title = "Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel",

abstract = "Introduction: Uterine serous carcinoma (USC) is more aggressive than other subtypes of endometrial carcinoma and is associated with a poor prognosis. We analyzed the metabolomic profile of USC with acquired resistance to paclitaxel. Results: Glutathione (GSH) concentration in PTX-1 cells was higher than in USPC- 1 cells. In addition, GSH concentration in the USPC-1 cells increased after treatment with paclitaxel but was unchanged in PTX-1 cells. Glucose-6-phosphate (G6P) and ribose-5-phosphate (R5P) concentrations in PTX-1 cells were higher than those in USPC-1 cells. G6P concentration in the USPC-1 cells was unchanged after treatment with paclitaxel, while it decreased in PTX-1 cells. Conclusion: Our results indicate that increased GSH and glucose metabolism may be related to acquiring resistance to paclitaxel in USC and thus may be targets for anti-USC therapy. Materials and Methods: We compared metabolic profiles and reactions to paclitaxel in both a wild type USC cell line (USPC-1) and PTX-1, a cell line derived from USPC-1 which acquired paclitaxel resistance, using a capillary electrophoresis CE-MS/MS system.",

keywords = "Endometrial cancer, Metabolomic analysis, Paclitaxel, Uterine serous carcinoma",

author = "Manabu Seino and Tsuyoshi Ohta and Akiko Sugiyama and Hirotsugu Sakaki and Takeshi Sudo and Seiji Tsutsumi and Shogo Shigeta and Hideki Tokunaga and Masafumi Toyoshima and Nobuo Yaegashi and Satoru Nagase",

note = "Publisher Copyright: {\textcopyright}Seino et al.",

year = "2018",

month = aug,

day = "10",

doi = "10.18632/oncotarget.25868",

language = "English",

volume = "9",

pages = "31985--31998",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "62",

}

TY - JOUR

T1 - Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel

AU - Seino, Manabu

AU - Ohta, Tsuyoshi

AU - Sugiyama, Akiko

AU - Sakaki, Hirotsugu

AU - Sudo, Takeshi

AU - Tsutsumi, Seiji

AU - Shigeta, Shogo

AU - Tokunaga, Hideki

AU - Toyoshima, Masafumi

AU - Yaegashi, Nobuo

AU - Nagase, Satoru

N1 - Publisher Copyright: ©Seino et al.

PY - 2018/8/10

Y1 - 2018/8/10

N2 - Introduction: Uterine serous carcinoma (USC) is more aggressive than other subtypes of endometrial carcinoma and is associated with a poor prognosis. We analyzed the metabolomic profile of USC with acquired resistance to paclitaxel. Results: Glutathione (GSH) concentration in PTX-1 cells was higher than in USPC- 1 cells. In addition, GSH concentration in the USPC-1 cells increased after treatment with paclitaxel but was unchanged in PTX-1 cells. Glucose-6-phosphate (G6P) and ribose-5-phosphate (R5P) concentrations in PTX-1 cells were higher than those in USPC-1 cells. G6P concentration in the USPC-1 cells was unchanged after treatment with paclitaxel, while it decreased in PTX-1 cells. Conclusion: Our results indicate that increased GSH and glucose metabolism may be related to acquiring resistance to paclitaxel in USC and thus may be targets for anti-USC therapy. Materials and Methods: We compared metabolic profiles and reactions to paclitaxel in both a wild type USC cell line (USPC-1) and PTX-1, a cell line derived from USPC-1 which acquired paclitaxel resistance, using a capillary electrophoresis CE-MS/MS system.

AB - Introduction: Uterine serous carcinoma (USC) is more aggressive than other subtypes of endometrial carcinoma and is associated with a poor prognosis. We analyzed the metabolomic profile of USC with acquired resistance to paclitaxel. Results: Glutathione (GSH) concentration in PTX-1 cells was higher than in USPC- 1 cells. In addition, GSH concentration in the USPC-1 cells increased after treatment with paclitaxel but was unchanged in PTX-1 cells. Glucose-6-phosphate (G6P) and ribose-5-phosphate (R5P) concentrations in PTX-1 cells were higher than those in USPC-1 cells. G6P concentration in the USPC-1 cells was unchanged after treatment with paclitaxel, while it decreased in PTX-1 cells. Conclusion: Our results indicate that increased GSH and glucose metabolism may be related to acquiring resistance to paclitaxel in USC and thus may be targets for anti-USC therapy. Materials and Methods: We compared metabolic profiles and reactions to paclitaxel in both a wild type USC cell line (USPC-1) and PTX-1, a cell line derived from USPC-1 which acquired paclitaxel resistance, using a capillary electrophoresis CE-MS/MS system.

KW - Endometrial cancer

KW - Metabolomic analysis

KW - Paclitaxel

KW - Uterine serous carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85054937613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054937613&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.25868

DO - 10.18632/oncotarget.25868

M3 - Article

AN - SCOPUS:85054937613

SN - 1949-2553

VL - 9

SP - 31985

EP - 31998

JO - Oncotarget

JF - Oncotarget

IS - 62

ER -

Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this